The global nephroblastoma therapeutics is slated to reach a valuation of US$ 2.12 billion in 2023. According to Future Market Insights, the market is expected to grow at a 9.88% CAGR until 2033, valued at US$ 5.44 billion.
The key factors driving the revenue growth of the nephroblastoma therapeutics market are the rapidly increasing population of newborn babies and increased funding for healthcare infrastructure and facilities by the government. Furthermore, extensive research and development activities in the cancer disease and an increase in awareness amongst the people regarding cancer are also expected to support the market revenue growth.
The high cost associated with the treatment and diagnosis of cancer is the major factor restraining the revenue growth of the market. In addition, side effects related to the treatment of cancer are also expected to hamper the revenue growth of the global Wilms market to some extent.
Extensive research and development activities in the field of cancer treatment and the use of modern technology for research purposes are expected to create significant revenue growth opportunities in the market. Many key players are working on developing a novel cancer treatment that is expected to create lucrative revenue growth opportunities for new entrants in the market.
North America is expected to account for the largest revenue share in the global nephroblastoma therapeutics market because of the increasing prevalence of the nephroblastoma disease in children followed by the Asia-Pacific is expected to be the fastest growing market in terms of revenue, due to the increasing prevalence of the Wilms tumor and a rapidly increasing population of newborn babies in this region.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2023) | US$ 2.12 billion |
| Projected Forecast Value (2033) | US$ 5.44 billion |
| Growth rate | 9.88% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global nephroblastoma therapeutics market grew at a CAGR of 8.88% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
Although most patients with a histological diagnosis of Wilms tumor do well with current treatment, approximately 10% of patients have histopathological features that are associated with a worse prognosis, and in some types, with a high incidence of relapse and death.
Nowadays, improved risk stratification has divided the population of patients into small subgroups, creating the challenge of designing and executing clinical trials that are sufficiently powered to demonstrate the desired outcomes. The fruits of stepped-up international collaboration are beginning to be realized, with the discovery of new genes, biological markers, and therapeutic targets. The benefits of COG-SIOP collaboration will hopefully translate into the application of evidence-based diagnostic and therapeutic approaches in low-income countries.
Increase in approvals of regulatory bodies
Key players in the market are focused on receiving approvals from regulatory bodies for drugs used to treat nephroblastoma is expected to drive the market growth over the forecast period.
Frequent regulatory approvals for new nephroblastoma treatments are expected to propel the growth of the global nephroblastoma treatment market during the forecast period. Market players are focusing on approvals from regulatory authorities for new drugs.
Focusing on the growth of R&D activities
Moreover, market players are focusing on R&D activities for new treatments, which is also expected to augment the growth of the global nephroblastoma treatment market during the forecast period. For instance, in August 2022, Children’s Oncology Group studying the combination of chemotherapy and surgery effects on young patients suffering from Wilms tumor revealed to be in Phase 3 trial and that the study is likely to be completed by end of the year 2023.
Principal Consultant
The high cost of treatment leads acts as a restraining factor
The major factor that hinders the growth of the global nephroblastoma therapeutics market includes the high cost of nephroblastoma. According to an article published by the American Society of Clinical Oncology, the cost for the full course of treatment was determined between US$ 1490 and US$ 2093 for a patient suffering from nephroblastoma.
Favorable reimbursement policies offering moneymaking opportunities in the United States
The United States is known for its healthcare infrastructure and favorable reimbursement scenario as both of them are expected to push the demand for nephroblastoma treatment shortly. A rise in the incidence of different types of tumors, rapid adoption of novel cancer treatments, and an increase in investment in medical research and development are also expected to favor market growth in the future.
Increasing investments in healthcare infrastructural development will favor market growth in Japan
Demand for nephroblastoma treatment is expected to be primarily driven by an increasing focus on healthcare infrastructure development and a rise in investments in medical R&D, the growing awareness regarding nephroblastoma, an increase in spending patterns on health and fitness, and the growing availability of novel cancer treatments with a rise in the number of cases are the factors that will augment the development of the market over the next ten years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Dactinomycin is said to hold a dominant share of the market
According to the reports of FMI, of 13 children treated with dactinomycin in addition to nephrectomy and postoperative radiotherapy, 92% (12 of 13) are living and free of tumors. It was concluded that the survival of children with nephroblastoma is markedly prolonged by the administration of dactinomycin at the time of diagnosis. The beneficial effect of dactinomycin was attributed to the ‘cidal’ action of this drug on small or poorly established metastases.
The demand for hospital pharmacies will be more during the forecast period.
According to a report by Future Market Insights, the hospital pharmacies would grow within the anticipated time frame. This market sector is expected to hold a greater share of the worldwide market from 2023 to 2033.
Due to the growing number of people visiting hospitals for advice on treatment related to nephroblastoma, the hospital pharmacy is anticipated to dominate the worldwide nephroblastoma therapeutics market. As a result, individuals more pertain towards their health and well-being. Thus, the majority of consumers are expected to only buy medications from hospital pharmacies.
The Soonicorns - soon to be Unicorns - are the handful of highly valued startups that have successfully grown out of their nascency to attract valuations of over a few hundred million. Watch out for these companies in the coming years as they take on the journey to becoming elite Unicorns.
Penn Medicine’s Abramson Cancer Center published early data from the first USA clinical trial of CRISPR-edited immune cells, showing that genetically editing the T cells of human cancer patients and infusing the cells back into the patients appeared safe and feasible. Investigators reported infusing three participants - two with multiple myeloma and one with sarcoma.
Some of the prominent players in the global market for Nephroblastoma Therapeutics Market treatment are
Some of the important developments of the key players in the market are
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 9.88% from 2023 to 2033 |
| Market value in 2023 | US$ 2.12 Billion |
| Market value in 2033 | US$ 5.44 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD Billion for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization Scope | Available on Request |
Collaborations are speeding up drug development and treatment access.
Continuous R&D activities are supporting the discovery of novel treatments.
Personalized treatment approaches, innovative drug combinations, and minimally invasive surgical techniques.
Growing awareness, and breakthroughs in treatment choices are driving the industry.
North America and Europe are prominent regions in the market.
1. Executive Summary | Nephroblastoma Therapeutics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2032 5.3.1. Favorable histology 5.3.2. Anaplastic histology 5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2032 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Drug Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2032 6.3.1. Dactinomycin 6.3.2. Doxorubicin 6.3.3. Vincristine 6.3.4. Cyclophosphamide 6.3.5. Etoposide 6.3.6. Irinotecan 6.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2032 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2032 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2032 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2032 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Type 9.2.3. By Drug Type 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Type 9.3.3. By Drug Type 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Type 10.2.3. By Drug Type 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By Drug Type 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Type 11.2.3. By Drug Type 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By Drug Type 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2032 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Type 12.2.3. By Drug Type 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By Drug Type 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2032 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Type 13.2.3. By Drug Type 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By Drug Type 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2032 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Type 14.2.3. By Drug Type 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Type 14.3.3. By Drug Type 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2032 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Type 15.2.3. By Drug Type 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Type 15.3.3. By Drug Type 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Type 16.1.2.2. By Drug Type 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Type 16.2.2.2. By Drug Type 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Type 16.3.2.2. By Drug Type 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Type 16.4.2.2. By Drug Type 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Type 16.5.2.2. By Drug Type 16.5.2.3. By Distribution Channel 16.6. United kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Type 16.6.2.2. By Drug Type 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Type 16.7.2.2. By Drug Type 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Type 16.8.2.2. By Drug Type 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Type 16.9.2.2. By Drug Type 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Type 16.10.2.2. By Drug Type 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Type 16.11.2.2. By Drug Type 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Type 16.12.2.2. By Drug Type 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Type 16.13.2.2. By Drug Type 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Type 16.14.2.2. By Drug Type 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Type 16.15.2.2. By Drug Type 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Type 16.16.2.2. By Drug Type 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Type 16.17.2.2. By Drug Type 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Type 16.18.2.2. By Drug Type 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Type 16.19.2.2. By Drug Type 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Type 16.20.2.2. By Drug Type 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Type 16.21.2.2. By Drug Type 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Type 17.3.3. By Drug Type 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Merck & Co., Inc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Recordati Rare Diseases 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Pfizer Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Sun Pharmaceutical Industries Ltd. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Cipla Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Actiza Pharmaceutical Private Limited 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Teva Pharmaceutical Industries Ltd. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Alvogen 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Accord Healthcare Ireland Ltd. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Amneal Pharmaceuticals LLC. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Healthcare
March 2022
REP-GB-774
June 2022
250 pages
Explore Healthcare Insights
View Reports
Nephroblastoma Therapeutics Market
